BIM
CORT icon

BRC Investment Management’s Corcept Therapeutics CORT Stock Holding History

BRC Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-11,978
Closed -$60K – 119
2015
Q4 		$60K Sell
11,978
-115
-1% -$519 0.01% 108
2015
Q3 		$45K Buy
+12,093
New +$61.4K 0.01% 111

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BRC Investment Management's CORT Position: Q1 2016 in Review

BRC Investment Management sold out of Corcept Therapeutics (CORT) in Q1 2016, closing a stake of 11,978 shares — an estimated $60K sold.

BRC Investment Management first reported a position in CORT in Q3 2015 and held it in 2 quarters. The position peaked at $60K in Q4 2015. 96 funds tracked by Wall St. Rank hold CORT as of Q1 2016.

  • BRC Investment Management reported no remaining Corcept Therapeutics position as of Q1 2016 after selling out during the quarter.
  • BRC Investment Management sold 11,978 Corcept Therapeutics shares in Q1 2016, an estimated $60K.
  • BRC Investment Management first reported a position in Corcept Therapeutics in Q3 2015 and held it in 2 quarters.
  • BRC Investment Management's Corcept Therapeutics position peaked at $60K in Q4 2015.
  • 96 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2016.

Based on BRC Investment Management's 13F filing for Q1 2016, filed 26 Apr 2016.